Choriogonadotropina alfa: interakcje
Choriogonadotropina alfa (Ovidrel): 60 udokumentowanych interakcji w indeksowanych przez nas etykietach FDA i kartach informacyjnych. Poważne: 37, umiarkowane: 23, niewielkie: 0, pary, dla których etykieta nie zgłasza istotnej interakcji: 0. Każda pozycja poniżej cytuje zdanie, na którym się opiera. Ta strona leku to punkt wyjścia, a nie rozstrzygnięcie dla indywidualnej sytuacji.
Interakcje z etykiety
Poważne interakcje (37)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (etykieta leku Choriogonadotropina alfa, Przeciwwskazania)
Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (etykieta leku Choriogonadotropina alfa, Przeciwwskazania)
Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (etykieta leku Choriogonadotropina alfa, Przeciwwskazania)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (etykieta leku Choriogonadotropina alfa, Przeciwwskazania)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (etykieta leku Choriogonadotropina alfa, Przeciwwskazania)
Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (etykieta leku Choriogonadotropina alfa, Przeciwwskazania)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Umiarkowane interakcje (23)
PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (etykieta leku Choriogonadotropina alfa, Środki ostrożności)
PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (etykieta leku Choriogonadotropina alfa, Środki ostrożności)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (etykieta leku Choriogonadotropina alfa, Środki ostrożności)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
- Gonadotropina kosmówkowaUmiarkowana
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (etykieta leku Choriogonadotropina alfa, Środki ostrożności)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etykieta leku Choriogonadotropina alfa, Ostrzeżenia)
The indices most generally used are as follows: A rise in basal body temperature Increase in serum progesterone and Menstruation following a shift in basal body temperature Urinary or serum luteinizing hormone (LH) rise When used in conjunction with the indices of progesterone production, sonographic visualization of the ovaries will assist in determining if… (etykieta leku Choriogonadotropina alfa, Środki ostrożności)
PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (etykieta leku Choriogonadotropina alfa, Środki ostrożności)
Sprawdź, jak Choriogonadotropina alfa łączy się ze wszystkim, co przyjmujesz. Dodaj całą listę; wszystkie pary są sprawdzane jednocześnie.
Otwórz w wyszukiwarceTo nie jest porada medyczna. Stopień nasilenia odzwierciedla sformułowania etykiety, a nie indywidualne okoliczności. Oznaczenie „poważna” może dotyczyć połączenia stosowanego rutynowo pod nadzorem, a „niewielka” może mieć znaczenie przy dużych dawkach. Należy zapytać farmaceutę.